BURDEN OF ILLNESS: DIRECT AND INDIRECT ECONOMIC COSTS OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UNITED STATES
Author(s)
Tiffanie Tran, PharmD1, Kimberly M Deininger, PhD, MPH1, Greg Kricorian, MD1, Joyce Qian, PhD, MPH2, Fiona Herr, PhD2, Alexis Sohn, PharmD, MPH, MS1.
1Amgen Inc., Thousand Oaks, CA, USA, 2Kyowa Kirin, Inc., Princeton, NJ, USA.
1Amgen Inc., Thousand Oaks, CA, USA, 2Kyowa Kirin, Inc., Princeton, NJ, USA.
OBJECTIVES: To describe economic burden of moderate-to-severe atopic dermatitis (M2SAD) in the US.
METHODS: This retrospective observational study used administrative claims data from 01Jan2017-31Dec2023 to describe patient characteristics, all-cause and AD-related healthcare resource utilization (HCRU), healthcare costs (HCC), AD-related treatment utilization, and oral corticosteroids (OCS) dosage over a fixed 24-month follow-up among patients >12yo with M2SAD. Absenteeism and associated indirect costs were assessed for adults (18-64yo). Eligible patients were identified based on the first systemic treatment or topical ruxolitinib claim within 30 days of the first of ≥2 separate AD diagnosis claims from 01Jan2018-31Dec2021.
RESULTS: Among all 25,269 patients (mean 42.5yo; 61.3% female; mean Charlson Comorbidity Index [CCI], 0.7), majority (61.8%) initiated systemic corticosteroids (SCS), 34.2% advanced therapy (AT; biologics, JAKis or topical ruxolitinib), and 4.0% systemic immunosuppressants (SIS) at index. During follow up, SCS remained the most common treatment for all patients (80.7%), followed by topical corticosteroids (71.5%), AT (37.0%), and SIS (6.9%). 89.3% of patients had AD-related outpatient office visits, most commonly with dermatologists (49.7%), primary-care (30.8%), and allergist/immunologists (15.1%).
Among the adolescents subgroup (N=3,346; mean 14.6yo; 57.2% female; mean CCI, 0.4) 36.9% initiated AT, 2.5% SIS, and 60.5% SCS at index. During follow up, SCS remained most used (73.6%), followed by topical corticosteroids (68.5%), AT (39.8%), and SIS (4.1%). 92.8% of patients had AD-related outpatient visits, most commonly with dermatologists (47.5%) and allergist/immunologists (24.8%).
Mean total all-cause HCC was $27,255 per-patient-per-year for adults (18-64yo; N=19,177) and $21,200 for adolescents, with 44.6% attributable to AD management (adults) vs 60.4% (adolescents). Mean annual productivity losses (N=413) attributable to absenteeism per employee was $4,760.
CONCLUSIONS: AD management contributed substantially to total HCC. Despite lower overall spending, AD-related costs and specialist use was higher in adolescents vs. adults. Findings highlight unmet needs and support continued improvement in M2SAD management to lessen economic burden.
METHODS: This retrospective observational study used administrative claims data from 01Jan2017-31Dec2023 to describe patient characteristics, all-cause and AD-related healthcare resource utilization (HCRU), healthcare costs (HCC), AD-related treatment utilization, and oral corticosteroids (OCS) dosage over a fixed 24-month follow-up among patients >12yo with M2SAD. Absenteeism and associated indirect costs were assessed for adults (18-64yo). Eligible patients were identified based on the first systemic treatment or topical ruxolitinib claim within 30 days of the first of ≥2 separate AD diagnosis claims from 01Jan2018-31Dec2021.
RESULTS: Among all 25,269 patients (mean 42.5yo; 61.3% female; mean Charlson Comorbidity Index [CCI], 0.7), majority (61.8%) initiated systemic corticosteroids (SCS), 34.2% advanced therapy (AT; biologics, JAKis or topical ruxolitinib), and 4.0% systemic immunosuppressants (SIS) at index. During follow up, SCS remained the most common treatment for all patients (80.7%), followed by topical corticosteroids (71.5%), AT (37.0%), and SIS (6.9%). 89.3% of patients had AD-related outpatient office visits, most commonly with dermatologists (49.7%), primary-care (30.8%), and allergist/immunologists (15.1%).
Among the adolescents subgroup (N=3,346; mean 14.6yo; 57.2% female; mean CCI, 0.4) 36.9% initiated AT, 2.5% SIS, and 60.5% SCS at index. During follow up, SCS remained most used (73.6%), followed by topical corticosteroids (68.5%), AT (39.8%), and SIS (4.1%). 92.8% of patients had AD-related outpatient visits, most commonly with dermatologists (47.5%) and allergist/immunologists (24.8%).
Mean total all-cause HCC was $27,255 per-patient-per-year for adults (18-64yo; N=19,177) and $21,200 for adolescents, with 44.6% attributable to AD management (adults) vs 60.4% (adolescents). Mean annual productivity losses (N=413) attributable to absenteeism per employee was $4,760.
CONCLUSIONS: AD management contributed substantially to total HCC. Despite lower overall spending, AD-related costs and specialist use was higher in adolescents vs. adults. Findings highlight unmet needs and support continued improvement in M2SAD management to lessen economic burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE403
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)